Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Completed Initiated Nov 14, 2023 (3 years ago)

Ondansetron Injection (Ondansetron Hydrochloride)

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Failed pH Specifications

Cause type: Failed specification

A physical or chemical test other than potency, dissolution, impurity or stability failed - pH, viscosity, appearance, tablet integrity, fill volume. A product outside its own specification may not perform as designed, even if the active ingredient is present. All failed specification recalls.

What was recalled

Ondansetron Injection, USP, 4 mg/2 mL (2 mg/mL), 2 mL per vial, Rx only, Manufactured for: Baxter Healthcare Corporation, Deerfield, IL 60015 USA. Manufactured by: Baxter Pharmaceuticals India Private Ltd, Ahmedabad 382213, India. NDC 36000-012-25

Affected NDC 36000-0012-25

Compare with the code on your package — it is the most precise check available.

Drug: Ondansetron Category: Heartburn & Stomach Medication

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Ondansetron Hydrochloride
NDC 36000-0012
2 mg/mL Solution
Intramuscular|intravenous
Baxter Healthcare Corporation Rx
Recalling firm
Baxter Healthcare Corporation
NDC code
36000-012-25
Origin
IL, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0146-2024 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now completed, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Ondansetron recalls

See all
Class II · Moderate risk

Ondansetron Orally Disintegrating Tablets

Defective container: Preferred Pharmaceuticals received a letter from the manufacturer Glenmark, that the blister packs are not fully sealed and tablets falling out. Preferred Pharmaceuticals purchased the finished product and repackaged the product for sale.

Ongoing Packaging defect Glenmark Pharmaceuticals Inc., USA NDC 68462-157-13 D-0246-2026
Class II · Moderate risk

Ondansetron ODT Tablets

Defective container: Preferred Pharmaceuticals received a letter from the manufacturer Glenmark, that the blister packs are not fully sealed and tablets falling out. Preferred Pharmaceuticals purchased the finished product and repackaged the product for sale.

Ongoing Packaging defect Preferred Pharmaceuticals, Inc. NDC 68788-8666-01 D-0239-2026
Class II · Moderate risk

Ondansetron HCL

cGMP deviations: Temperature abuse

Terminated Temperature excursion Mckesson Medical-Surgical Inc. Corporate Office NDC 65862-188-30 D-1103-2022

Other recalls by Baxter Healthcare Corporation

All 2023 recalls
Class I · High risk

Dextrose Injection

Presence of Particulate Matter: particulate matter identified as stainless steel particles in the solution.

Ongoing Particulate / foreign matter Baxter Healthcare Corporation NDC 00338-0719-06 D-0850-2026
Class II · Moderate risk

Daptomycin

CGMP Deviations

Ongoing cGMP deviation Baxter Healthcare Corporation NDC 0338-0718-12 D-0821-2026